Search Results
Your search for ,OUr matches 10724 pages
Showing 51 - 100Unique Phase I NSCLC Trial Sites Decreasing in United States
The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant consolidation of studies to only high trial volume sites in the country, according to the results of a...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252). Although it’s known that...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
Injecting the PD-1 inhibitor nivolumab directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial (ClinicalTrials.gov identifier NCT05327270) presented at the American Association for Cancer ...
Methylation-Based AI Model Classifies Tumors of Unknown Origin
An artificial intelligence (AI) model using DNA methylation patterns was able to classify tumors of unknown origin with high accuracy, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 3869). “One of the most...
Metastatic NSCLC: Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non–small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual ...
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel led to a 100% measurable residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the...
Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC
Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C inhibitor or not, according to findings from an ongoing phase I/II clinical trial presented at the ...
Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an...
ASCO Expands TAPUR Trial With Two New Precision Drug Arms
ASCO has expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) study with two new developments: The study added its first antibody-drug conjugate (ADC), fam-trastuzumab deruxtecan-nxki (T-DXd), to determine if a wider group of patients would benefit from this medicine....
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
Patients with advanced platinum-resistant ovarian cancer who had experienced disease progression on standard therapy exhibited clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according to results from a phase I clinical trial (ClinicalTrials.gov...
Melanoma: Can AI Enable Diagnosis Prediction?
Assessment of machine-learning models tested on Swedish registry data enabled more accurate melanoma diagnosis prediction, with added health-care code, age, sex, and medication information for improved performance, according to the results of a study published in Acta Dermato-Venereologica. “Our...
AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers
Researchers have developed an artificial intelligence (AI) tool that can identify small groups of cells most responsible for driving aggressive cancers. The tool, called SIDISH, offers scientists a clearer path to designing targeted therapies by showing which cells inside a tumor are most strongly...
DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors
A large prospective evaluation of off-label targeted cancer therapies has shown that more patients could potentially benefit from existing drugs. After including over 1,600 patients in the Dutch multicenter Drug Rediscovery Protocol (DRUP) trial (ClinicalTrials.gov identifier NCT02925234), the...
AYA Cancer Survivors and Risk for Earlier Subsequent Primary Neoplasms
About one in six survivors of an adolescent and young adult cancer will develop a subsequent primary neoplasm within 30 years of their original diagnosis, according to the results of a population-based study published in the Canadian Medical Association Journal. “When combined with the relatively...
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded his facial nerve. Several weeks ago, when the PA’s fingers moved over the mass visibly protruding...
Nancy L. Lewis, MD, MBS, FACP, Named NCCN’s New Chief Scientific Officer
The National Comprehensive Cancer Network® (NCCN®) has announced the selection of Nancy L. Lewis, MD, MBS, FACP, as its new Chief Scientific Officer (CSO). Dr. Lewis is an experienced biomedical researcher with expertise in clinical trials for treating solid tumors and hematologic malignancies....
POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy
For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a...
Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients
In a UK retrospective cohort study reported in The Lancet Oncology, Whitworth et al analyzed the frequency of germline genetic variants in patients with cancer in the 100,000 Genomes Project. Study Details The study included data from 14,765 individuals with cancer entered into the 100,000 Genomes...
Electroacupuncture May Relieve Cognitive, Psychological Symptoms in Breast Cancer Survivors in Pilot Study
Electroacupuncture may alleviate some persistent neuropsychiatric symptoms experienced by breast cancer survivors, including psychological distress and cognitive impairment, according to the results of a randomized, double-blinded pilot trial published in the Journal of the National Cancer...
Antoni Ribas, MD, PhD, Honored With the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) will present the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research to Antoni Ribas, MD, PhD, Fellow of the AACR Academy, during the AACR Annual Meeting 2026, to be held April 17 to 22 in San Diego. Dr. ...
Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center
International leader in blood cancer and stem cell research Ulrich Steidl, MD, PhD, has been named Director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Vice President of Cancer Medicine at Montefiore Einstein. He has acted as Interim Director of MECCC, which is a National...
How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs
As the data continue to show, the incidence of breast, testis, and other cancers are on the rise in adolescent and young adults (AYAs) between the ages of 15 and 39, with increases of 30% over the last 4 decades.1 And while potential explanations for this rapid increase have included obesity,...
New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research
In collaboration with St. Jude Children's Research Hospital and the Munich Leukemia Laboratory, the American Society for Hematology has introduced the ASH HematOmics Program (ASHOP), which may be one of the most comprehensive collections of blood cancer data ever to accelerate discovery, according...
Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC
Long-term follow-up of the oral selective RET inhibitor pralsetinib in patients with advanced non–small cell lung cancer (NSCLC) and a RET fusion confirms its efficacy and safety, according to final findings from the phase I/II ARROW trial published in the Journal of Clinical Oncology. “Before...
Low Food Access May Lead to More Complications After Breast Reconstruction
Researchers have identified a possible link between living in an area of lower food access and postoperative outcomes and complications after breast reconstruction, according to study results published in Plastic and Reconstructive Surgery. "Our findings suggest that access to healthy foods and...
Ablative Radiotherapy May Improve Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma
A new study published by Jaoude et al in Clinical Cancer Research demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma. The retrospective study was led ...
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
The National Comprehensive Cancer Network® (NCCN®) brought together more than a thousand oncology professionals at the NCCN 2026 Annual Conference in Orlando, with hundreds more joining virtually. This year’s event featured educational sessions on breakthroughs in cancer prevention and treatment,...
Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC
Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findings from a prospective cohort study published in The Lancet Regional Health: Americas. “As our...
Prompting Strategies May Improve Symptom Monitoring in Childhood Cancer Survivors
Prompting strategies on two large language models improved how the artificial intelligence (AI) interpreted pain and fatigue reported by survivors of childhood cancers for better symptom monitoring and care, according to findings published in Communications Medicine. The study authors noted that...
FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
The U.S. Food and Drug Administration (FDA) has granted traditional approval to the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The full approval now includes efficacy, safety, and...
Presence of ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer may predict whether they are likely to experience relapse—especially when samples are taken after the patients have received treatments prior to surgery. Findings presented at the 15th European Breast Cancer...
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
An interpretable machine-learning framework, called PRE-Screen-HCC, may predict risk levels for developing hepatocellular carcinoma (HCC) more accurately than publicly available risk scores, according to findings from a large population-based multicentric study published in Cancer Discovery. “Our...
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-line setting, according to findings presented during the first European Society for Medical...
Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery
Patients with breast cancer may be able to avoid lymphedema, which can occur after surgery to remove lymph nodes in the axilla, by having radiotherapy instead. New findings, presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona, suggest that axillary radiotherapy may be as...
Two Major Cancer Centers Announce Appointments of New Directors
Last week, Dartmouth Cancer Center (DCC) and Fox Chase Cancer Center announced the appointments of new directors—both experts in the treatment of lung cancer. DCC has appointed Roy S. Herbst, MD, PhD, as the center’s sixth director. Temple Health announced the appointment of Robert A. Winn, MD, as...
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
In patients with CALR exon 9–mutated myelofibrosis who were resistant or intolerant to prior Janus kinase (JAK) inhibitor therapy, or ineligible for such treatment, the first-in-class mutant calreticulin–specific monoclonal antibody INCA033989, given as monotherapy or in combination with...
AI As Collaborator in Cancer Research and in Clinical Care
Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identified patient datasets from participating cancer centers, while maintaining patient security,...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
Breast Cancer Recurrence Remains Low—Even After 10 Years—With Radiotherapy Tailored to Patient’s Individual Risk
The chances of breast cancer recurring remain low when patients are treated with radiotherapy that is tailored to their individual risk following chemotherapy and surgery. These are the findings of a 10-year Dutch study (RAPCHEM; BOOG 2010-03) presented at the 15th European Breast Cancer Conference ...
Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery
Women who are treated with mastectomy for breast cancer often choose to have breast reconstructive surgery using an implant. But hard, painful scar tissue can form around the implant, especially when women also receive radiotherapy as part of their treatment. Findings from the OPBC-09 PRExRT study, ...
Hyperplasia and the Link Between Obesity and Cancer
Research has uncovered that an increase in organ size from hyperplasia due to increased weight may increase the risk for several obesity-related cancers, according to findings published in Cancer Research. “People have long been told that obesity increases cancer risk, but they are rarely told...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
How AI Is Already Having a Significant Impact on Cancer Care
Three education sessions presented during the 2025 ASCO Annual Meeting showcased how artificial intelligence (AI) is quickly transforming cancer care from clinical trial planning and ambient scribes transcribing physician-patient conversations to therapeutic decision-making. The meeting also...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
The Thymus Plays a Part in Adult Cancer Risk and Treatment Response, Research Reveals
Two papers published in Nature reveal long-disregarded functions of the thymus in adulthood, showing that the overall health of the organ impacts aging and risks for cardiovascular disease and cancer, as well as affecting response to immunotherapy in patients with cancer. “The thymus has been...
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers have found a combination of the tyrosine kinase inhibitor tucatinib and the monoclonal antibody trastuzumab, plus the chemotherapy capecitabine, may improve symptoms and extend survival in some...
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
As the incidence of cancer among reproductive-age people continues to increase in the United States—with approximately one out of every 1,000 pregnancies complicated by cancer—the Society for Maternal-Fetal Medicine (SMFM) has issued its first evidence-based clinical guidance for diagnosing and...
Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
A new analysis suggests that prostate cancer screening may compare favorably with screening for breast cancer in terms of identifying significant cancers, reducing mortality, and avoiding unnecessary harms, according to findings presented at the 2026 Annual Congress of the European Association of...
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria
One in 10 patients who present to the emergency department with visible hematuria may die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study, presented at the European Association of Urology Congress (EAU26) in London, found that a scan administered within 48...
